

1/48




FIG. 1A

SUBSTITUTE SHEET (RULE 26)

2/48






FIG. 1B

3/48

**FIG. 2**

4/48

**FIG. 3**

SAD: TEAEs reported by at least 1 Participant in any BC Dose Group							
System Organ Class/ Preferred Term	Placebo (n=12)	20 mg (n=6)	60 mg (n=6)	100 mg (n=6)	140 mg (n=6)	220 mg (n=6)	360 mg (n=6)
	Events Subjects N N (%)	Events Subjects N N (%)	Events Subjects N N (%)	Events Subjects N N (%)	Events Subjects N N (%)	Events Subjects N N (%)	Events Subjects N N (%)
ANY EVENTS	5 3 (25)	9 5 (83)	18 5 (83)	25 6 (100)	32 6 (100)	49 6 (100)	41 6 (100)
Psychiatric Disorders	1 1 (8)	4 2 (33)	6 4 (67)	10 5 (83)	9 5 (83)	16 6 (100)	11 5 (83)
Affect lability			1 1 (17)				
Anxiety			1 1 (17)	1 1 (17)			2 2 (33)
Apathy			1 1 (17)				
Bradypnea					1 1 (17)	1 1 (17)	1 1 (17)
Burnout syndrome		1 1 (17)					
Depressed mood					1 1 (17)		
Dissociation			1 1 (17)	1 1 (17)	1 1 (17)	4 3 (50)	2 2 (33)
Disturbance in attention				2 2 (33)	3 3 (50)	2 2 (33)	
Emotional distress							1 1 (17)
Euphoric mood				2 2 (33)	2 2 (33)	2 2 (33)	1 1 (17)
Illusion		1 1 (17)					
Insomnia						1 1 (17)	
Overconfidence						1 1 (17)	
Restlessness							1 1 (17)
Self-consciousness	1 1 (8)	1 1 (17)	1 1 (17)	1 1 (17)			
Suicidal ideation							1 1 (17)
Thinking abnormal				1 1 (17)			
Time Perception Altered		1 1 (17)	1 1 (17)	2 2 (33)	1 1 (17)	5 5 (83)	2 2 (33)

FIG. 4

SAD: TEAEs reported by at least 1 Participant in any BC Dose Group							
System Organ Class/ Preferred Term	Placebo (n=12)	20 mg (n=6)	60 mg (n=6)	100 mg (n=6)	140 mg (n=6)	220 mg (n=6)	360 mg (n=6)
	Events N (%)	Subjects N (%)	Events N (%)	Subjects N (%)	Events N (%)	Subjects N (%)	Events N (%)
ANY EVENTS	5 3 (25)	9 5 (83)	18 5 (83)	25 6 (100)	32 6 (100)	49 6 (100)	41 6 (100)
NERVOUS SYSTEM DISORD.	3 2 (17)	1 1 (17)	8 4 (67)	6 4 (67)	12 6 (100)	12 5 (83)	15 6 (100)
Altered State of Consciousness						1 1 (17)	3 3 (50)
Bradykinesia				1 1 (17)			
Dizziness			1 1 (17)		4 4 (67)	3 3 (50)	6 6 (100)
Dizziness, postural				1 1 (17)	1 1 (17)	1 1 (17)	
Headache	2 2 (17)		1 1 (17)	1 1 (17)	2 2 (33)	1 1 (17)	
Hyperaesthesia			1 1 (17)				
Hypoesthesia				1 1 (17)			
Paraesthesia			1 1 (17)	1 1 (17)	1 1 (17)	3 3 (50)	2 2 (33)
Sensory Proc. d/o			1 1 (17)		1 1 (17)		2 2 (33)
Slow response to stimuli					3 3 (50)	2 2 (33)	
Somnolence		1 1 (17)					
Tinnitus						1 1 (17)	
Tremor							1 1 (17)
Vertigo							1 1 (17)

FIG. 5

7/48





FIG. 6

8/48

**FIG. 7**

SUBSTITUTE SHEET (RULE 26)




FIG. 8A

10/48




FIG. 8B




FIG. 8C

12/48




FIG. 8D

SUBSTITUTE SHEET (RULE 26)

13/48




FIG. 9




FIG. 10

15/48




FIG. 11

16/48




FIG. 12

SUBSTITUTE SHEET (RULE 26)

Base Cmpd Dose	SBP CFB @ 30 min
Placebo	2.7 mmHg
20 mg	1.3
60 mg	4.7
100 mg	5.7
140 mg	10.6
220 mg	10.8
360 mg	19.2

FIG. 13




FIG. 14

19/48




FIG. 15

20/48




FIG. 16




FIG. 17





FIG. 18A-18B




FIG. 18C-18D




FIG. 19A-19D




FIG. 20A-20D

26/48

BC MAD: Dose-dependent increases in mild/moderate TEAEs							
System Organ Class	Pbo Events	Pbo Subjs N(%)	140 mg Events N	140mg Subjs N(%)	220 mg Events N	220 mg Subjs N(%)	Preferred Terms in 4/9 Subjs
Any Events	6	1(16.7%)	136	9(100%)	191	9(100%)	
Gastrointestinal Disorders	1	1(17%)	10	3(33%)	21	7(78%)	Nausea
General Disorders & Administration Site	1	1(17%)	10	3(33%)	34	9(100%)	Fatigue
Nervous System Disorders	3	1(17%)	68	9(100%)	62	9(100%)	Dizziness Sensory process disorders Somnolence
Psychiatric Disorders	---	-----	39	9(100%)	51	9(100%)	Dissociation Euphoric Mood Altered time Perception

LEGEND

Pbo-Placebo

N-Number

Subjs-Subjects

FIG. 21






FIG. 22

28/48

**FIG. 23A**

SUBSTITUTE SHEET (RULE 26)

29/48

**FIG. 23B**

SUBSTITUTE SHEET (RULE 26)

30/48




FIG. 24A




FIG. 24B




FIG. 25A




FIG. 25B

34/48




FIG. 26A

B) CMS - Experimental Schedule




FIG. 26B

36/48




FIG. 26C

37/48

D) Elevated Plus Maze




FIG. 26D

38/48

E) Novel Object Recognition





FIG. 26E

39/48

F) Sucrose Intake- Single dose durability**FIG. 26F**

G) Sucrose Intake- Oral administration




FIG. 26G

A) Spontaneous Locomotor Activity (sLMA)








FIG. 27A

42/48

B) Rotarod**FIG. 27B**

43/48

C) Conditioned Place Preference (CPP)**FIG. 27C**

D) Napiergram





FIG. 27D

45/48



46/48




FIG. 28B

47/48




FIG. 28C

48/48




FIG. 28D